<DOC>
	<DOCNO>NCT00087191</DOCNO>
	<brief_summary>This clinical trial study amount EF5 motexafin lutetium present tumor cell and/or normal tissue patient abdominal ( ovarian , colon , stomach cancer ) non-small cell lung cancer . EF5 may effective measure oxygen tumor tissue . Photosensitizing drug motexafin lutetium absorb tumor cell , expose light , become active kill tumor cell . Knowing level oxygen tumor tissue level motexafin lutetium absorb tumor normal tissue may help predict effectiveness anticancer therapy</brief_summary>
	<brief_title>EF5 Motexafin Lutetium Detecting Tumor Cells Patients With Abdominal Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine uptake motexafin lutetium tumor normal tissue patient intra-abdominal malignancy non-small cell lung cancer . II . Determine ratio tumor normal tissue measure level motexafin lutetium uptake tumor normal tissue remove patient . III . Determine pattern , presence , level EF5 binding ( surrogate marker hypoxia ) tumor patient . IV . Determine feasibility measure optical property , tissue oxygenation , motexafin lutetium concentration , fluorescence , blood flow non-invasive mean patient . OUTLINE : This multicenter , diagnostic study . Patients stratify accord diagnosis ( intra-abdominal malignancy v non-small cell lung cancer ) . Patients receive EF5 IV 1-2.5 hour day 1 motexafin lutetium IV 10-15 minute day 2 . Patients undergo definitive surgical resection approximately 3 hour motexafin lutetium administration . Hypoxia motexafin lutetium level resect tumor evaluate . Tumor normal tissue ratio also determine . After completion study treatment , patient follow approximately 1-8 week . PROJECTED ACCRUAL : A total 30 patient ( 20 intra-abdominal malignancy 10 non-small cell lung cancer ) accrue study within 10-15 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Motexafin lutetium</mesh_term>
	<criteria>Histologically confirm suspect diagnosis 1 following : Intraabdominal malignancy 1 follow type : Sarcoma Ovarian cancer Gastrointestinal malignancy , include , limited , appendiceal cancer , colon cancer , gastric cancer Nonsmall cell lung cancer Planning undergo surgical resection disease Disease propensity spread peritoneal cavity ( intraabdominal malignancy patient ) Performance status ECOG 02 WBC ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin &lt; 1.5 mg/dL Creatinine normal Creatinine clearance ≥ 60 mL/min Body weight ≤ 130 kg No G6PD deficiency No porphyria No history peripheral neuropathy ≥ grade 3 Able tolerate anesthesia major surgery Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>